Download PDF
Thromb Haemost 2001; 86(04): 1047-1056
DOI: 10.1055/s-0037-1616532
Special Article
Schattauer GmbH

A Hamster Antibody to the Mouse Fibrinogen Chain Inhibits Platelet-fibrinogen Interactions and FXIIIa-mediated Fibrin Cross-linking, and Facilitates Thrombolysis

Markéta JirouȈsková
1   Department of Medicine, Mount Sinai School of Medicine, New York, NY
,
Susan S. Smyth
1   Department of Medicine, Mount Sinai School of Medicine, New York, NY
,
Bohdan Kudryk
2   Laboratory of Blood Coagulation Biochemistry, New York Blood Center, New York, NY, USA
,
Barry S. Coller   *
1   Department of Medicine, Mount Sinai School of Medicine, New York, NY
› Author Affiliations
Further Information

Publication History

Received 28 February 2001

Accepted after revision 21 May 2001

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Summary

Murine models employing genetically altered mice have the potential to provide important new information about the hemostatic system, but before such data can be extrapolated to humans it is necessary to define the similarities and differences between murine and human hemostasis. After establishing the similarities of murine fibrinogen to human fibrinogen in its pattern of proteolysis in response to plasmin and its cross-linking by factor XIIIa, we studied a new hamster monoclonal antibody (mAb) 7E9 that reacts with the γ chain of mouse fibrinogen. This antibody inhibits platelet adhesion to fibrinogen, platelet-mediated clot retraction, platelet aggregation, and FXIIIa-mediated cross-linking of fibrin; it also facilitates tissue plasminogen activator (tPA)-mediated lysis of fibrin formed either in the absence or presence of platelets. These data provide evidence that the C-terminus of mouse fibrinogen γ chain, like that of human fibrinogen, is involved in fibrinogen binding to platelets and FXIIIa-mediated cross-linking of fibrin. Our data raise the possibility that a therapeutic agent that targets the C-terminus of the γ chain in human fibrinogen might have broad antithrombotic and profibrinolytic effects.

Keywords

Fibrinogen - thrombolysis - factor XIIIa - antithrombotic therapy

* This work was supported in part by grants 19278 and 54469 from the National Heart, Lung and Blood Institute to B.S.C.


 

  • References

  • 1 Kloczewiak M, Timmons S, Hawiger J. Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the gamma chain of human fibrinogen and is not involved in the fibrin polymerization reaction. Thromb Res 1983; 29: 249-55.
    CrossrefPubMedGoogle Scholar
  • 2 Cheresh DA, Berliner SA, Vicente V, Ruggeri ZM. Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell 1989; 58: 945-53.
    CrossrefPubMedGoogle Scholar
  • 3 Farrell DH, Thiagarajan P. Binding of recombinant fibrinogen mutants to platelets. J Biol Chem 1994; 269: 226-31.
    PubMedGoogle Scholar
  • 4 Chen R, Doolittle RF. γ-γ-cross-linking sites in human and bovine fibrin. Biochemistry 1971; 10: 4487-91.
    CrossrefPubMedGoogle Scholar
  • 5 Gartner TK, Amrani DL, Derrick JM, Kirschbaum NE, Matsueda GR, Taylor DB. Characterization of adhesion of “resting” and stimulated platelets to fibrinogen and its fragments. Thromb Res 1993; 71: 47-60.
    CrossrefPubMedGoogle Scholar
  • 6 Taubenfeld SM, Song Y, Sheng D, Ball EL, Matsueda GR. A monoclonal antibody against a peptide sequence of fibrinogen gamma chain acts as an inhibitor of factor XIII-mediated crosslinking of human fibrin. Thromb Haemost 1995; 74: 923-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Holmback K, Danton MJ, Suh TT, Daugherty CC, Degen JL. Impaired platelet aggregation and sustained bleeding in mice lacking the fibrinogen motif bound by integrin alpha IIb beta 3. EMBO J 1996; 15: 5760-71.
    PubMedGoogle Scholar
  • 8 Lengweiler S, Smyth SS, Jirouskova M, Scudder LE, Park H, Moran T, Coller BS. Preparation of monoclonal antibodies to murine platelet glycoprotein IIb/IIIa (alphaIIbbeta3) and other proteins from hamster-mouse interspecies hybridomas. Biochem Biophys Res Commun 1999; 262: 167-73.
    CrossrefPubMedGoogle Scholar
  • 9 Harlow E, Lane D. Antibodies: A Laboratory Manual. 1988
    PubMedGoogle Scholar
  • 10 Scudder LE, Kalomiris EL, Coller BS. Preparation and functional characterization of monoclonal antibodies against glycoprotein Ib. Methods Enzymol 1992; 215: 295-311.
    PubMedGoogle Scholar
  • 11 Kudryk B, Grossman ZD, McAfee JG, Rosenbrough SF. Monoclonal antibodies as probes for fibrin(ogen) proteolysis. In: Monoclonal Antibodies in Immunoscintigraphy. Chatal J-F. ed. Boca Raton, Florida: CRC Press; 1989: 365-98.
    Google Scholar
  • 12 Coller BS, Ward P, Ceruso M, Scudder LE, Springer K, Kutok J, Prestwich GD. Thrombin receptor activating peptides: importance of the N-terminal serine and its ionization state as judged by pH dependence, nuclear magnetic resonance spectroscopy, and cleavage by aminopeptidase M. Biochemistry 1992; 31: 11713-20.
    CrossrefPubMedGoogle Scholar
  • 13 Song YC, Sheng D, Taubenfeld SM, Matsueda GR. A microtiter assay for factor XIII using fibrinogen and biotinylcadaverine as substrates. Anal Biochem 1994; 223: 88-92.
    CrossrefPubMedGoogle Scholar
  • 14 Procyk R, Bishop PD, Kudryk B. Fibrin-recombinant human factor XIII a-subunit association. Thromb Res 1993; 71: 127-38.
    CrossrefPubMedGoogle Scholar
  • 15 Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA 1995; 92: 7450-4.
    CrossrefPubMedGoogle Scholar
  • 16 Law DA, Nannizzi-Alaimo L, Ministri K, Hughes PE, Forsyth J, Turner M, Shattil SJ, Ginsberg MH, Tybulewicz VL, Phillips DR. Genetic and pharmacological analyses of Syk function in alphaIIbbeta3 signaling in platelets. Blood 1999; 93: 2645-52.
    PubMedGoogle Scholar
  • 17 Hodivala-Dilke KM, McHugh KP, Tsakiris DA, Rayburn H, Crowley D, Ullman-Cullere M, Ross FP, Coller BS, Teitelbaum S, Hynes RO. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 1999; 103: 229-38.
    CrossrefPubMedGoogle Scholar
  • 18 Thorsen LI, Brosstad F, Gogstad G, Sletten K, Solum NO. Binding of 125I-labelled fibrin(ogen) fragments to platelets and to immunoprecipitated glycoprotein IIb-IIIa complex. Thromb Res 1986; 42: 645-59.
    CrossrefPubMedGoogle Scholar
  • 19 Thorsen LI, Brosstad F, Gogstad G, Sletten K, Solum NO. Competitions between fibrinogen with its degradation products for interactions with the platelet-fibrinogen receptor. Thromb Res 1986; 44: 611-23.
    CrossrefPubMedGoogle Scholar
  • 20 Lorand L. Research on clot stabilization provides clues for improving thrombolytic therapies. Arterioscler Thromb Vasc Biol 2000; 20: 2-9.
    CrossrefPubMedGoogle Scholar
  • 21 Freund KF, Doshi KP, Gaul SL, Claremon DA, Remy DC, Baldwin JJ, Pitzenberger SM, Stern AM. Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry 1994; 33: 10109-19.
    CrossrefPubMedGoogle Scholar
  • 22 Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992; 267: 24259-63.
    PubMedGoogle Scholar
  • 23 Langer BG, Weisel JW, Dinauer PA, Nagaswami C, Bell WR. Deglycosylation of fibrinogen accelerates polymerization and increases lateral aggregation of fibrin fibers. J Biol Chem 1988; 263: 15056-63.
    PubMedGoogle Scholar
  • 24 Francis CW, Marder VJ, Barlow GH. Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure. J Clin Invest 1980; 66: 1033-1043.
    CrossrefPubMedGoogle Scholar
  • 25 Francis CW, Marder VJ. A molecular model of plasmic degradation of crosslinked fibrin. Semin Thromb Hemost 1982; 8: 25-35.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Smyth SS, Reis ED, Vaananen H, Zhang W, Scudder LE, Coller BS. Mice lacking GPIIb/IIIa and αVβ3 are variably protected from thrombosis, depending on the mechanism of thrombus initiation. Blood. 2001 in press.
    PubMedGoogle Scholar
  • 27 Ryan EA, Mockros LF, Stern AM, Lorand L. Influence of a natural and a synthetic inhibitor of factor XIIIa on fibrin clot rheology. Biophys J 1999; 77: 2827-36.
    CrossrefPubMedGoogle Scholar
  • 28 Chen R, Doolittle RF. Identification of the polypeptide chains involved in the cross-linking of fibrin. Proc Natl Acad Sci USA 1969; 63: 420-7.
    CrossrefPubMedGoogle Scholar
  • 29 Doolittle RF, Chen R, Lau F. Hybrid fibrin: proof of the intermolecular nature of γ-γ cross-linking units. Biochem Biophys Res Commun 1971; 44: 94-100.
    CrossrefPubMedGoogle Scholar
  • 30 McKee PA, Mattock P, Hill RL. Subunit structure of human fibrinogen, soluble fibrin, and cross-linked insoluble fibrin. Proc Natl Acad Sci USA 1970; 66: 738-44.
    CrossrefPubMedGoogle Scholar
  • 31 Denis C, Methia N, Frenette PS, Rayburn H, Ullman-Cullere M, Hynes RO, Wagner DD. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A 1998; 95: 9524-9.
    CrossrefPubMedGoogle Scholar
  • 32 Credo RB, Curtis CG, Lorand L. Alpha-chain domain of fibrinogen controls generation of fibrinoligase (coagulation factor XIIIa). Calcium ion regulatory aspects. Biochemistry 1981; 20: 3770-8.
    CrossrefPubMedGoogle Scholar
  • 33 Mary A, Achyuthan KE, Greenberg CS. Factor XIII binds to the A alpha-and B beta-chains in the D-domain of fibrinogen: An immunoblotting study. Biochem Biophys Res Commun 1987; 147: 608-14.
    CrossrefPubMedGoogle Scholar
  • 34 Matsueda GR, Bernatowicz MS. Characterization of a monoclonal antibody that binds to the carboxyl-terminus of the fibrin gamma-chain. In Fibrinogen 3 – Biochemistry, Biological Functions, Gene Regulation and Expression. Mosesson MW, Amarni DL, Siebenlist KR, DiOrio JP. eds. Amsterdam: Elsevier Science Publishers B V.; 1988: 133-6.
    Google Scholar
  • 35 Siebenlist KR, Mosesson M W. Evidence of intramolecular cross-linked A alpha.gamma chain heterodimers in plasma fibrinogen. Biochemistry 1996; 35: 5817-21.
    CrossrefPubMedGoogle Scholar
  • 36 Shainoff JR, Urbanic DA, DiBello PM. Immunoelectrophoretic characterizations of the cross-linking of fibrinogen and fibrin by factor XIIIa and tissue transglutaminase. Identification of a rapid mode of hybrid alpha-/ gamma-chain cross-linking that is promoted by the gamma-chain cross-linking. J Biol Chem 1991; 266: 6429-37.
    PubMedGoogle Scholar
  • 37 Rosenberg RD, Colman RW, Lorand L. A new haemorrhagic disorder with defective fibrin stabilization and cryofibrinogenaemia. Br J Haematol 1974; 26: 269-84.
    CrossrefPubMedGoogle Scholar
  • 38 Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42.
    CrossrefPubMedGoogle Scholar
  • 39 Coller BS. Augmentation of thrombolysis with antiplatelet drugs. Coron Artery Dis 1995; 6: 911-4.
    PubMedGoogle Scholar
  • 40 Hantgan RR, Mousa SA. Inhibition of platelet-mediated clot retraction by integrin antagonists. Thromb Res 1998; 89: 271-9.
    CrossrefPubMedGoogle Scholar
  • 41 Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38.
    CrossrefPubMedGoogle Scholar
  • 42 Diamond SL, Anand S. Inner clot diffusion and permeation during fibrinolysis. Biophys J 1993; 65: 2622-43.
    CrossrefPubMedGoogle Scholar
  • 43 Kunitada S, FitzGerald GA, Fitzgerald DJ. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 1992; 79: 1420-7.
    PubMedGoogle Scholar
  • 44 Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood 1994; 83: 351-6.
    PubMedGoogle Scholar
  • 45 Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81: 1290-9.
    PubMedGoogle Scholar
  • 46 Sakata Y, Aoki N. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536-42.
    CrossrefPubMedGoogle Scholar